Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Matson Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Matson Inc trades at $214.74 (market cap $6.11B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.8× Matson Inc's market cap, and Matson Inc pays a 0.74% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MATX | |
|---|---|---|
Market Cap | $29.60B | $6.11B |
Sector | Health | Technology |
52-Week High | $491.22 | $223.55 |
52-Week Low | $205.48 | $88.05 |
Enterprise Value | $27.56B | $6.71B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Matson (MATX) trades at $214.45, up 2.76% with strong earnings momentum after beating Q2 2026 EPS estimates of $3.79 with $4.27 actual. The stock shows bullish technical signals with support at $200 and resistance at $209. Fundamentally, the company maintains solid profitability with 13.41% net margin and 17.21% ROE, supported by raised full-year guidance after strong Q2 results.
MATX presents a compelling investment case with 27.3% upside to consensus price target of $265, supported by 66.7% analyst buy ratings. Key risks include exposure to Trans-Pacific trade volatility and competitive shipping markets, but resilient consumer demand and premium China service position the company for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
